Core research and drug-development guides
Practical resources on experimental methods, translational research, biostatistics, clinical development, precision medicine, and regulatory decision-making.
Epidemiology
• Jan 2025
A review of American Cancer Society 2025 estimates, including stage at diagnosis, relative survival trends, and why population-level associations should not be mistaken for causal explanations.
menu_book Read Article
Molecular Biology
• May 2026
The DRT3 anti-phage system combines RNA- and protein-templated DNA synthesis. We examine the original mechanism and how later experiments refined hypotheses about its role in bacterial defense.
menu_book Read Article
Epidemiology & Public Health
• May 2026
An examination of invitation to colonoscopy in the NordICC trial, including the absolute difference in colorectal cancer diagnoses and the distinction between screening uptake, cancer incidence, and mortality outcomes.
menu_book Read Article
Advanced Therapeutics
• May 2026
A review of selected gene-therapy and genome-editing developments, distinguishing regulatory milestones and early clinical signals from evidence of long-term safety, durability, and broad effectiveness.
menu_book Read Article
Clinical Trial Strategy
• Jun 2026
Explore how developers navigated an FDA rejection due to cardiac toxicity, strategically pivoted their clinical trial design to a frontline combination therapy, and ultimately secured approval for Quizartinib.
menu_book Read Article
Molecular Biology
• Sep 2026
A study of DNA-guided Cas12a RNA targeting, what the reported experiments establish about guide design and RNA cleavage, and why therapeutic safety and efficacy require disease-specific follow-up studies.
menu_book Read Article
Clinical Trial Strategy
• Jul 2026
A case study of the early CPKC412A2104 core cohort, in which Novartis used a prespecified response threshold of at least 2 of 12 participants as a program-specific PoC decision rule. The article distinguishes that early decision from blast-response findings in the separate 95-patient Phase IIb extension and explains why 2/12 is not a universal PoC standard.
menu_book Read Article
Clinical Trial Design
• May 2026
An interpretation of the PASHA randomized trial's neutral overall-survival result alongside relapse and relapse-free survival findings, including how post-relapse treatment patterns inform—but do not prove—the explanation for OS.
menu_book Read Article
Biostatistics
• May 2026
A comparison of sample-size approaches used in menin-inhibitor trials, including the assumptions behind single-arm response-rate designs and the limits of interpreting statistical power as a guarantee of trial success or approval.
menu_book Read Article
Regulatory Affairs
• Mar 2026
A comparative analysis of the core requirements to transition a drug from the bench to human clinical trials, synthesizing FDA and MFDS guidelines.
menu_book Read Article
Computational Biology
• Feb 2024
A review of FRoGS compound-target prediction benchmarks, the distinction between model-scored candidates and experimentally validated interactions, and the limits of generalizing benchmark performance to drug discovery.
menu_book Read Article
Precision Medicine
• Aug 2015
A historical case study of the original BRACAnalysis CDx approval with olaparib, including the defined intended use and why biomarker eligibility and predictive value must be interpreted in the context of current labeling and study design.
menu_book Read Article
Regulatory Policy
• Dec 2024
An overview of accelerated approval, confirmatory-trial expectations, endpoint selection, and the distinction between an unmet confirmatory endpoint and a conclusion that a treatment has no benefit on every outcome.
menu_book Read Article
Clinical Trial Design
• Updated Nov 2026
A practical review of factorial designs, external comparator evidence, endpoint selection, and the FDA's nonbinding 2025 draft guidance for demonstrating each component's contribution in novel oncology combinations.
menu_book Read Article
Precision Oncology
• Apr 2020
Understanding FDA's push towards precision medicine by allowing broader labeling of companion diagnostic devices.
menu_book Read Article
Pharmacology
• Aug 2024
A practical development-stage framework for enzyme- and transporter-mediated DDI assessment, including when in-vitro signals may justify modeling or clinical studies and where M12's scope does not extend.
menu_book Read Article
Clinical Oncology
• Updated Nov 2026
A sponsor-side review of FDA's July 2026 final guidance on performance status, laboratory values, washout periods, and concomitant medications, with practical protocol questions and design considerations.
menu_book Read Article
Computational Biology
• Aug 2026
A review of research linking repeated-token divergence to attention-sink circuitry, with a careful look at what the findings do—and do not—establish for biological applications.
menu_book Read Article
Neuroscience
• Oct 2024
How a connectome-based leaky integrate-and-fire model of the adult fruit fly central brain predicted selected sensorimotor responses, and what its experimental validation does—and does not—show.
menu_book Read Article
Neuroengineering
• Nov 2016
A review of a preclinical brain–spinal interface study in macaques, explaining the constrained neural-decoding task, experimental locomotion findings, and why these results do not establish clinical effectiveness in people.
menu_book Read Article
Behavioral Science
• Jun 2006
A review of a 2006 Science study on social modulation of pain-related behavior in mice, distinguishing the observed behavioral findings from interpretations about subjective empathy.
menu_book Read Article